N/A
Manufactured by Alcon Laboratories, Inc.
11,458 FDA adverse event reports analyzed
Last updated: 2026-04-15
KETOTIFEN FUMARATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Alcon Laboratories, Inc.. The most commonly reported adverse reactions for KETOTIFEN FUMARATE include TREATMENT FAILURE, DRUG INEFFECTIVE, EYE IRRITATION, EYE PAIN, OCULAR HYPERAEMIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for KETOTIFEN FUMARATE.
Out of 6,341 classified reports for KETOTIFEN FUMARATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 11,458 FDA FAERS reports that mention KETOTIFEN FUMARATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TREATMENT FAILURE, DRUG INEFFECTIVE, EYE IRRITATION, EYE PAIN, OCULAR HYPERAEMIA, EYE PRURITUS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Alcon Laboratories, Inc. in connection with KETOTIFEN FUMARATE. Always verify the specific product and NDC with your pharmacist.